U.S. markets close in 2 hours 52 minutes
  • S&P 500

    -0.40 (-0.01%)
  • Dow 30

    -28.54 (-0.09%)
  • Nasdaq

    +57.32 (+0.43%)
  • Russell 2000

    -18.84 (-0.87%)
  • Crude Oil

    -0.13 (-0.24%)
  • Gold

    -2.00 (-0.11%)
  • Silver

    +0.06 (+0.23%)

    +0.0041 (+0.34%)
  • 10-Yr Bond

    +0.0110 (+1.01%)

    +0.0056 (+0.41%)

    -0.0350 (-0.03%)

    -3,223.15 (-9.22%)
  • CMC Crypto 200

    -52.20 (-7.68%)
  • FTSE 100

    -24.97 (-0.37%)
  • Nikkei 225

    +233.60 (+0.82%)

Exact Sciences (EXAS) Soars: Stock Adds 9.8% in Session

Zacks Equity Research
·2 min read

Exact Sciences Corporation EXAS was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $124.28 to $142.12 in the past one-month time frame.

The company has seen one positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Exact Sciences. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road. 

Exact Sciences currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Exact Sciences Corporation Price

Exact Sciences Corporation Price
Exact Sciences Corporation Price

Exact Sciences Corporation price | Exact Sciences Corporation Quote

A better-ranked stock in the Medical - Biomedical and Genetics industry is Arcus Biosciences, Inc. RCUS, holding a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
Arcus Biosciences, Inc. (RCUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research